Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sevy

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
L'Encephale|November 1, 1985
[Pharmacology and clinical aspects of benzodiazepines]J Mendlewicz, S Sevy
Schizophrenia Bulletin|January 1, 1990
Pyramidical model of schizophreniaS R Kay, S Sevy
Life Sciences|January 1, 1993
Minireview: Molecular genetics in affective illnessJ Mendlewicz, S Sevy, K Mendelbaum
Neuropsychobiology|January 1, 1989
REM sleep latency and morbidity risk of affective disorders in depressive illnessJ Mendlewicz, S Sevy, V de Maertelaer
Schizophrenia Bulletin|February 5, 2002
Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophreniaS Sevy, K Nathanson, C Schechter, et al.
Biological Psychiatry|January 15, 1989
Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjectsS Sevy, G N Papadimitriou, D W Surmont, et al.
The Journal of Nervous and Mental Disease|October 1, 1990
Significance of cocaine history in schizophreniaS Sevy, S R Kay, L A Opler, et al.
Biological Psychiatry|June 15, 1994
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazineR S Kahn, M Davidson, L J Siever, et al.
Neuropsychobiology|January 1, 1989
Alpha-2-adrenoreceptor binding as a possible vulnerability marker for affective disordersJ Mendlewicz, D Hirsch, S Sevy, et al.
The American Journal of Psychiatry|August 1, 1989
Defense mechanisms in risk of suicide and risk of violenceA Apter, R Plutchik, S Sevy, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
L'Encephale|November 1, 1985
[Pharmacology and clinical aspects of benzodiazepines]J Mendlewicz, S Sevy
Schizophrenia Bulletin|January 1, 1990
Pyramidical model of schizophreniaS R Kay, S Sevy
Life Sciences|January 1, 1993
Minireview: Molecular genetics in affective illnessJ Mendlewicz, S Sevy, K Mendelbaum
Neuropsychobiology|January 1, 1989
REM sleep latency and morbidity risk of affective disorders in depressive illnessJ Mendlewicz, S Sevy, V de Maertelaer
Schizophrenia Bulletin|February 5, 2002
Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophreniaS Sevy, K Nathanson, C Schechter, et al.
Biological Psychiatry|January 15, 1989
Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjectsS Sevy, G N Papadimitriou, D W Surmont, et al.
The Journal of Nervous and Mental Disease|October 1, 1990
Significance of cocaine history in schizophreniaS Sevy, S R Kay, L A Opler, et al.
Biological Psychiatry|June 15, 1994
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazineR S Kahn, M Davidson, L J Siever, et al.
Neuropsychobiology|January 1, 1989
Alpha-2-adrenoreceptor binding as a possible vulnerability marker for affective disordersJ Mendlewicz, D Hirsch, S Sevy, et al.
The American Journal of Psychiatry|August 1, 1989
Defense mechanisms in risk of suicide and risk of violenceA Apter, R Plutchik, S Sevy, et al.
Pageof 2